TRAXENS
3.6.2019 08:32:12 CEST | Business Wire | Press release
Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will be introducing its comprehensive solutions portfolio aimed at the maritime and rail freight industries at Transport Logistic (June 4-7, Munich).
Traxens’ solutions provide comprehensive, precise and timely data about cargo by tracking wagons and smart containers in transit anywhere in the world through dedicated sensors, an Internet-of-Things network and a customized portal. Traxens’ technology brings improved efficiency and security, greater transparency and enhanced asset utilization thanks to improved wagon, container and goods tracking, geolocalisation and ambient temperature monitoring.
The rail freight industry could enjoy the benefits of a number of rail
projects Traxens has accomplished with partners. In co-operation with
SNCF Logistics, Traxens has trialled a Digital Freight Train, where a
number of smart wagons equipped with Traxens-boxes were successfully
tracked on their way to European destinations as well as China. Accurate
real-time data from the whole train led to improved efficiency as well
as cost reductions.
In addition to this, Traxens also offers
digital brake testing, which can bring up to thirty minutes time-saving
on standard re-allocation processes, real-time alerts on the brake
system and significantly reduced operational costs.
“Traxens’ offering for rail freight was instrumental in bringing transparency to our operations for the digital future. A great example is the digital brake test, which brings us significant time savings at reallocation processes, improved cost and operational efficiency thanks to real-time monitoring of brake systems en route, as well as enhanced work conditions,” said Marc Valette, innovation director, CFL multimodal.
Bertrand MINARY, Chief Innovation officer at Fret SNCF said: “ It is an absolute necessity to transport more goods via rail freight to preserve our planet. Improved efficiency and new services will convince customers to move more cargo on rail instead of road freight by 2030, as suggested by the European Rail Freight Forward initiative. In order to improve reliability, we worked together with Traxens on the Digital Freight Train. For SNCF Logistics, Traxens’ unique, easy-to-implement, innovative, affordable and energy-efficient solution is simply the best to achieve that.“
For the maritime sector, Traxens provides door-to-door data monitoring solutions for smart containers (both dry and reefers) and has already signed agreement with dozens of Beneficial Cargo Owners, such as Tesco Global.
“The Traxens unit has provided us with unprecedented insights into our container movements, supplier performance and landside operation. It has the potential to shape the way we can use reliable data driven insights to manage our end-to-end operation, take strategic action and ultimately reduce costs, waste and lead-times,” said Peter Downs, Senior Logistics Performance Manager, Global Logistics at Tesco Global.
Traxens will be present at Booth A3.628 at Transport Logistic in Munich (4-7 June).
About Traxens
Traxens generates, collects, consolidates,
enriches and transforms logistics asset data into actionable insight for
its clients in the maritime, rail and supply chain industries.
The
company’s breakthrough Internet-of-Big-Things technology provides
comprehensive, real-time information for managing logistics assets
anywhere in the world. Traxens’ solutions digitally transform
multi-modal supply chains, enabling customers to reduce costs, optimize
investments, comply with environmental regulations and deliver premium
services to their customers. Traxens’ IoT solution received the Frost &
Sullivan’s Technology Leadership Award in 2019.
www.traxens.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190602005024/en/
Contact:
PRESS: Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
